Checkmate Pharmaceuticals — Investor Presentation (December 2021)
24 slides from Checkmate Pharmaceuticals's investor presentation, Dec 14, 2021
Slide 1: Heating Up Cancer Immunotherapy
Heating Up Cancer Immunotherapy December 2021 Exhibit 99.1
Slide 2: Forward Looking Statement
Forward Looking Statement Certain statements in this presentation (“Presentation”) that are not statements of historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such forward-looking statements include tho
Slide 3: Investment Highlights
Investment Highlights Vidutolimod (CMP-001) is an innate immune modulator with the potential to become a backbone of I/O combinations 28% ORR in PD-1 refractory melanoma1; similar magnitude of regression in injected and non-injected lesions 67% pathologic response in PD-1 naïve neoadjuvant melanoma
Slide 4: Vidutolimod (CMP-001) can activate a T cell response
Vidutolimod (CMP-001) can activate a T cell response 30 nm Qbeta Potent Type A CpG DNA payload (G10) Native DNA backbone can be cleaved during TLR9 Structure mimics viral, retroviral DNA structures The strongest reported inducer of type I IFN by pDC G10 CpG-A Oligonucleotide Immune stimulating virus
Slide 5: Vidutolimod can reprogram the tumor microenvironment
Vidutolimod can reprogram the tumor microenvironment, stimulating a powerful systemic T cell response against a tumor 1 Antibody-bound vidutolimod is taken up by pDC and activates TLR9 2 Activated pDC recruit and stimulate other immune cells; Type I IFN enhances T cell activation directly and indire
Slide 6: CpG-A Induces the Highest Type I IFN, and Lowest Inflammatory Cytokine
CPG-A Induces the Highest Type I IFN, and Lowest Inflammatory Cytokine 1OOR = out of range IFN-α IL-6 TNF IL-10 IL-1β Luminex cytokine/chemokine multiplex of supernatants from normal human PBMC, performed using optimal conditions and concentrations for each agent at the University of Iowa Cancer Cen
Slide 7: Systemic Effect via Local Activation
Systemic Effect via Local Activation Intratumoral injection (i.e., in situ immunization) directly stimulates anti-tumor CD8+ T cell immunity to neoantigens CD8+ T cells traffic systemically, attack noninjected lesions Requires a single lesion accessible for injection Cutaneous or subcutaneous lesion
Slide 8: Maturing and Expanding Set of Target Indications
Maturing and Expanding Set of Target Indications Note: Refractory Melanoma represents Anti PD-1 Refractory Melanoma, 1L Melanoma represents Anti PD-1 Naïve, Metastatic or Unresectable Melanoma, Neoadjuvant Melanoma represents Anti PD-1 Naïve, Neoadjuvant Melanoma, and First Line HNSCC represents Ant
Slide 9: Large and Growing Market Opportunity in Melanoma
Large and Growing Market Opportunity in Melanoma US Market1 High unmet need in melanoma with continued expected growth Standard of care Anti PD-1 (pembrolizumab or nivolumab) Opportunity Significant room for improvement vs. single agent anti PD-1 in front-line melanoma Single agent front-line anti P
Slide 10: Phase 1b Study in PD-1 Refractory Melanoma
Phase 1b Study in PD-1 Refractory Melanoma Prior cancer therapies Any PD-1 100% Any ipilimumab 47% Prior PD-1 best response CR (complete response) 4% PR (partial response) 13% SD (stable disease) 31% PD (progressive disease) 43% Prior PD-1 last response SD (stable disease) 3% PD (progressive disease
Slide 11: Clinically Meaningful Response in Refractory Patient Population
Clinically Meaningful Response in Refractory Patient Population 1RECISTv1.1, Data 17 August 2021 2RECISTv1.1 plus post-progression responses, Data cutoff August 17, 2021 3Response to treatment beyond progression with anti-PD-1. Ahmed, F.S., et al., Eur Radiol, 2020; 6/78 iPR/iCR after intial PD by R
Slide 12: Robust Depth of Response
Robust Depth of Response PD (progressive disease) . SD (stable disease) PR (partial response) CR (complete response) Post-PD response Change From Baseline of Target Lesions ( %) 120 100 80 60 40 20 -20 -40 -60 -80 -100 RECIST Partial Response: -30% Note: N=98 subjects who received formulation A, inc
Slide 13: Highly Durable Responses
Highly Durable Responses Note: N=37, RECIST v1.1 responders and Post-progression responders; Data cutoff September 30, 2020 Median duration of response 19.9 months RECIST v1.1 Disease Status CR PR SD PD Vidutolimod + Pembrolizumab No Vidutolimod treatment 6 month 1 year 2 years 3 years 4 years 0 6 1
Slide 14: Systemic (Abscopal) Effect Observed in Distant Visceral Lesions
Systemic (Abscopal) Effect Observed in Distant Visceral Lesions 48-year-old WF with metastatic bilateral lung disease Progressed after prior therapies of ipilimumab (adjuvant), interferon (adjuvant), pembrolizumab, IL-2, aflibercept Injection site: right inguinal lymph node (groin) Non-injected Targ
Slide 15: Systemic Effect Observed in Non-Injected Lesions
Systemic Effect Observed in Non-Injected Lesions Injected lesions, mean regression 71% Non-Injected lesions, mean regression 62% Responders with Injected Target Lesions Only (n=15) Responders with Non-Injected Target Lesions (n=22) RECIST Partial Response: -30% Note: N=37, RECIST v1.1 responders and
Slide 16: Vidutolimod Monotherapy Activity Supportive of Further Development
Vidutolimod Monotherapy Activity Supportive of Further Development In Combination Vidutolimod has shown monotherapy activity The median DOR (5.6 months; RECIST) is substantially shorter than that of combination therapy Supportive of further development in combination Data cutoff August 17, 2021 22.5
Slide 17: Treatment-Related Adverse Events Were Generally Manageable
Treatment-Related Adverse Events Were Generally Manageable No Grade 5 TRAE reported; Data cutoff: August 17, 2021 Vidutolimod + Pembrolizumab (n=159) Grade 3 or 4 Treatment-Related Adverse Events 37.1% (59/159) of subjects Most common (≥ 3 subjects): hypotension (n=11, 7%); hypertension (n=8, 5%); c
Slide 18: Neoadjuvant Study Design
Neoadjuvant Study Design1 1Davar et al, SITC 2020; Data cutoff: October 1, 2020 2Tetzlaff Ann Oncol 2018, 29 (8): 1861-1868. Pathologic Response2 Residual Viable Tumor MPR Complete Response (pCR) 0% Major Response (pMR) ≤10% Partial Response (pPR) >10% & <50% Non-Response (pNR) >50% Primary endpoint
Slide 19: Compelling Pathologic Response and 1 Year Relapse Free Survival
Compelling Pathologic Response and 1 Year Relapse Free Survival 1Davar Hillman Cancer Center Study 17-169, ClinicalTrials.gov Identifier: NCT03618641 September 16, 2021 2Tetzlaff Ann Oncol 2018, 29 (8): 1861-1868. [% Residual Viable Tumor: pCR = 0; pMR <10%; pPR 10 - 50%; pNR >50%] 3MPR = major path
Slide 20: Treatment-Related Adverse Events Were Generally Manageable
Treatment-Related Adverse Events Were Generally Manageable No delays or surgical complications related to therapy Davar et al, SITC 2020; Data cutoff: October 1, 2020; Data is based on preliminary analysis. Vidutolimod/Nivolumab (N=31) AE Term, N (%) Grade 1 (n/%) Grade 2 (n/%) Grade 3 (n/%) Grade 4
Slide 21: Next Steps for Vidutolimod Development
Next Steps for Vidutolimod Development Develop in combination with anti-PD-1 inhibitors Vidutolimod monotherapy data of 20% ORR (22.5% including post progressing responders) serves as unique differentiator among other innate immune activators However, combination therapy resulted in improved duratio
Slide 22: Vidutolimod Clinical Trials and Data Milestones
Vidutolimod Clinical Trials and Data Milestones Phase/Trial Design Trial Objective Anticipated 2022/2023 Milestones Melanoma Refractory* Ph 2 ongoing, n=100 PD-1 refractory patients Single arm, vidutolimod + nivo Registrational trial for potential BLA submission for accelerated approval Topline data
Slide 23: Experienced Management Team / Corporate Highlights
Experienced Management Team Headquarters in Cambridge, MA Completed IPO in August 2020 As of September 30, 2021 Cash and cash equivalents of $80.8M Common stock shares outstanding 21.6 million No debt Cash runway through end of 2022 Corporate Highlights
Slide 24: Investment Highlights
Investment Highlights Vidutolimod (CMP-001) is an innate immune modulator with the potential to become a backbone of I/O combinations 28% ORR in PD-1 refractory melanoma1; similar magnitude of regression in injected and non-injected lesions 67% pathologic response in PD-1 naïve neoadjuvant melanoma
Checkmate Pharmaceuticals — Investor Presentation (December 2021) on 6ix